Studies on agents with vasodilator and beta-blocking activities. II.
A series of phenoxypropanolamines having a hydrazinopyridazinyl moiety was synthesized. Their hypotensive and beta-blocking activities were evaluated after intravenous administration of the compounds to anesthetized rats. Some of them exhibited both activities. In particular, compound 20k is a candidate for clinical use due to its hypotensive activity, equal to that of hydralazine, and its beta-blocking activity, 2.7-fold more potent than that of propranolol.
Seki
T
T
Research Division, Teikoku Hormone Manufacturing Co., Ltd., Kanagawa, Japan.
Takezaki
T
T
Ohuchi
R
R
Ohuyabu
H
H
Tanimoto
Y
Y
Yamaguchi
T
T
Saitoh
M
M
Ishimori
T
T
Yasuda
K
K
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D006830:Hydralazine / Q000494:pharmacology; D007275:Injections, Intravenous; D011412:Propanolamines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D011724:Pyridazines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D011412:Propanolamines; D011724:Pyridazines; D014665:Vasodilator Agents; D006830:Hydralazine; D011433:Propranolol